Prostaglandin E2 alteration in contraceptive consumers: as a risk factor for inflammatory diseases
Sanjary Pour, M.; Fallah, S.; Rabbani Chadegani, A.
Archives of Gynecology and Obstetrics 287(5): 1031-1037
2013
ISSN/ISBN: 1432-0711 PMID: 23224727 DOI: 10.1007/s00404-012-2661-3Document Number: 565703
The aim of this study was to evaluate the effect of oral combined contraceptive pills on Prostaglandin E2 levels and lipid profiles. The enzyme-linked immune absorbent assay method and spectrophotometric assay were used for the evaluation of PGE2 levels and lipid profiles, respectively, in 50 healthy women with normal menstrual cycles who served as the control group and 50 women taking contraceptive pill. The data obtained for serum Prostaglandin E2, LDL-C, and cholesterol concentrations in contraceptive pill consumers were significantly upper (P = 0.04, 0.002, and 0.05, respectively) than control group. The age of contraceptive pill consumption and the duration of pill intake beyond 36 months had no significant effect on the prostaglandin E2 concentration. It is suggested that the increase of Prostaglandin E2 and atherogenic lipid levels may be related to their probable effects in response to various pathological and physiological properties of COCs.
Document emailed within 0-6 h
